Association between nasopharyngeal colonization with multiple pneumococcal serotypes and total pneumococcal colonization density in young Peruvian children.

"Declarations of Competing Interest L. M. H. has received grant support from Pfizer for unrelated work. K. M. E. reports grant funding from the National Institutes of Health and Centers for Disease Control and Prevention; has served as a consultant to Bionet and IBM; and has served as a member of Data Safety and Monitoring Boards for Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, and Roche. C. F. L. is a member of the World Health Organization COVID-19 vaccine effectiveness working group and reports grant funding from CureVac AG, PATH, and Hille-Vax from work not related to the current work. C. G. G. has served as a consultant to Pfizer, Merck, and Sanofi-Pasteur for unrelated work and received research support from Sanofi-Pasteur. All other authors report no potential conflicts of interest."

"Funding This work was supported by Vanderbilt University Clinical and Translational Science Award (grant number UL1 RR024975-01), investigator-initiated research grants from Pfizer (grant numbers IIR WS1898786 [0887 × 1-4492] and IIR WS2079099), the Thrasher Research Fund (grant number 02832-9), and the National Institutes of Health (grant number 1K23AI141621). The study sponsors had no role in the study design, collection or interpretation of data, in writing of the manuscript, and the decision to submit the manuscript for publication."